

## ASX Announcement 2 November 2020

### CEO Appointment and Resignation

**Regeneus Ltd (ASX: RGS) (Regeneus or the Company)**, a clinical-stage regenerative medicine company, advises that Leo Lee has resigned from his role as CEO of the Company to pursue a new role in a major Japanese pharmaceutical company. Mr Lee will remain on the Board of Regeneus as a Non-Executive Director, enabling the Company to benefit from his strategic leadership.

Following the resignation, the Board has appointed Karolis Rosickas as CEO, effective immediately.

Mr Rosickas is an experienced executive and healthcare entrepreneur with over 15 years business experience in healthcare, technology and finance, including in global businesses. He was most recently CEO and co-founder of OME Health, a nutrition technology business, and co-founded SingCell, a stem cell contract development and manufacturing organisation. Mr Rosickas has also held senior positions at HSBC, JP Morgan, Danone, Santander Group and KPMG in his career. He holds an MBA from IESE Business School and is CFA qualified.

Barry Sechos, Independent Chairman of Regeneus, said: "Leo's appointment in January 2019 was focused on securing a major licensing agreement and under his leadership, the Company has successfully achieved this with the Progenza deal with Kyocera. We thank Leo for his service and are delighted that the Company will continue to benefit from his strategic guidance as a Non-Executive Director."

"At the same time, we welcome Karolis as Regeneus' new CEO. His experience in the healthcare and finance sector will be invaluable for the Company, Furthermore, his experience as a co-founder of an organisation dedicated to stem cell development and manufacturing will be critical for Regeneus' next phase of growth."

The Board is in the process of determining the short and long-term incentive structures applicable to Mr Rosickas' role as CEO to ensure they are aligned with the next phase of growth for the Company. A summary of the material terms of Mr Rosickas' appointment will be separately provided to the market.

**-ENDS-**

#### About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on

neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit [www.regeneus.com.au](http://www.regeneus.com.au) for more information.

**Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Regeneus Ltd

**Investor and Media Contact**

WE Communications

T: 02 9237 2805

E: [WE-AURegeneus@we-worldwide.com](mailto:WE-AURegeneus@we-worldwide.com)